Arvinas teams up with Isogenica using our CIS display technology to expand their PROTAC® platform
Announcing a new collaboration with Arvinas
Isogenica is pleased to announce a technology license agreement with Arvinas, who will leverage Isogenica’s CIS Display technology in support of advancing and expanding its PROTAC® platform. This Arvinas license continues to validate Isogenica’s proprietary display platform.
Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialisation of therapies to degrade proteins that cause cancer, neurodegenerative diseases, and other disorders.
Arvinas uses their proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC® protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Isogenica is a biotechnology company specialising in the discovery and optimisation of highly versatile small format antibodies (VHHs), originally derived from camelids, which are used to construct next generation biotherapeutics for the treatment of cancer, inflammation, and other serious diseases. VHHs can be readily chained together and assembled to create bi- or multi-specific biotherapeutics, and also used for targeted drug delivery as components of ADCs or in cell and gene therapies including CAR-Ts.
Isogenica is a biotechnology company specializing in the discovery and development of small format single chain VHH antibodies. We are leaders in our domain, having developed a fully synthetic, in vitro plug-and-play cassette-based approach to efficiently generate combinations of bi- and tri-specific biotherapeutics. Drawing on more than 20 years at the forefront of antibody discovery and engineering, we have built a unique and proven engine for biotherapeutic development and a deep pipeline including two clinical stage assets and more than ten partnered pre-clinical and discovery stage programmes.
For further information, visit www.isogenica.com
Arvinas is a clinical-stage biotechnology company leading the way in the development of targeted protein degradation therapeutics. They are driving some of the most significant breakthroughs in the industry and enabling an expansive pipeline of targets in the fields of oncology and neuroscience. Arvinas’s PROTAC® Targeted Protein Degraders harness the body’s natural protein disposal system to destroy disease-causing proteins.
For further information, visit www.arvinas.com/
Business Development & Marketing Executive Isogenica
T +44 1799 533 680